Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Klea HoldingVMDGF 36 EV-to-EBIT is 12.59 as of Jul. 31, 2026. GuruFocus rates VMDGF with a GF Score™ of 36/100 and a GF Value™ of $0.43. The stock has 2 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Klea Holding ranks better than 73.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Klea Holding's Enterprise Value for the quarter that ended in Dec. 2025 was $137.87 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Klea Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $4.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klea Holding EV-to-EBIT Related Terms
Klea Holding EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Klea Holding's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Klea Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klea Holding EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Klea Holding's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Klea Holding's EV-to-EBIT falls into.
Klea Holding's current Enterprise Value is $55.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Klea Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $4.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klea Holding (VMDGF) has a EV-to-EBIT of 12.59 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Klea Holding and its competitors. According to the industry distribution chart, Klea Holding ranks #28 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 26.7%.
Is Klea Holding's EV-to-EBIT too high?
Klea Holding's current EV-to-EBIT is 12.59. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.47. Klea Holding's value of 12.59 is 46.4% below this industry median. Based on the distribution chart, Klea Holding ranks #28 out of 105 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Klea Holding has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Klea Holding's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Klea Holding ranks #28 out of 105 companies for EV-to-EBIT. This puts Klea Holding in the upper half of its industry. The industry median EV-to-EBIT is 23.47. Klea Holding's value of 12.59 is 46.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.47, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klea Holding's current EV-to-EBIT of 12.59 is 46.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Klea Holding and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klea Holding's current EV-to-EBIT is 12.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klea Holding stock overvalued right now?
Klea Holding (VMDGF) has a current EV-to-EBIT of 12.59. The stock's GF Value™ is $0.43, compared to a current price of $0.20 — trading 53.5% below its estimated fair value. The current EV-to-EBIT is 12.59 and 46.4% below the Medical Diagnostics & Research industry median of 23.47. Klea Holding's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Klea Holding (VMDGF), the current EV-to-EBIT is 12.59 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klea Holding (VMDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Klea Holding stock appears to be undervalued.
The current stock price of $0.20 is trading 53.5% below its estimated GF Value™ of $0.43.
Key valuation signals for VMDGF:
EV-to-EBIT: 12.59
GF Value™: $0.43 vs. price of $0.20 (53.5% below fair value)
Industry Position: 46.4% below the Medical Diagnostics & Research median (#28 of 105)
No single metric tells the full story. See the VMDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klea Holding focused on the acquisition, development and digitalization of companies in multiple sectors. Its development of Smart Salem, the first network of digital medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the Emirates United Arabs, or its Smart Health joint venture developed in Saudi Arabia.
36GF Score
Get the complete analysis for VMDGF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMDGF has been successfully added to your 
